- Home
- IMAB vs HOWL Comparison
IMAB vs HOWL Comparison
Compare IMAB & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- HOWL
- Stock Information
- Founded
- IMAB 2014
- HOWL 2017
- Country
- IMAB United States
- HOWL United States
- Employees
- IMAB N/A
- HOWL N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- HOWL Health Care
- Exchange
- IMAB Nasdaq
- HOWL Nasdaq
- Market Cap
- IMAB 83.8M
- HOWL 87.4M
- IPO Year
- IMAB 2020
- HOWL 2021
- Fundamental
- Price
- IMAB $0.94
- HOWL $1.62
- Analyst Decision
- IMAB Strong Buy
- HOWL Strong Buy
- Analyst Count
- IMAB 3
- HOWL 2
- Target Price
- IMAB $8.00
- HOWL $13.50
- AVG Volume (30 Days)
- IMAB 288.7K
- HOWL 411.3K
- Earning Date
- IMAB 08-28-2024
- HOWL 11-07-2024
- Dividend Yield
- IMAB N/A
- HOWL N/A
- EPS Growth
- IMAB N/A
- HOWL N/A
- EPS
- IMAB N/A
- HOWL N/A
- Revenue
- IMAB $3,313,984.00
- HOWL $3,386,000.00
- Revenue This Year
- IMAB N/A
- HOWL N/A
- Revenue Next Year
- IMAB N/A
- HOWL $34.17
- P/E Ratio
- IMAB N/A
- HOWL N/A
- Revenue Growth
- IMAB N/A
- HOWL N/A
- 52 Week Low
- IMAB $0.90
- HOWL $1.58
- 52 Week High
- IMAB $2.54
- HOWL $8.19
- Technical
- Relative Strength Index (RSI)
- IMAB 38.29
- HOWL 34.79
- Support Level
- IMAB $0.91
- HOWL $1.62
- Resistance Level
- IMAB $1.11
- HOWL $1.72
- Average True Range (ATR)
- IMAB 0.07
- HOWL 0.12
- MACD
- IMAB -0.00
- HOWL -0.01
- Stochastic Oscillator
- IMAB 13.01
- HOWL 6.12
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.